trial · primary record
Serplulimab, Docetaxel, Oxaliplatin, S1, and Lenvatinib combined with PIPAC
Gastric/Gastroesophageal Junction Adenocarcinoma
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 42 |
| Primary completion | 2028-12-31 |
| Primary endpoint | Surgery conversion rate |
| Registry ID | NCT07902648 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-29T14:33:36.876Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07902648
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.